Takehisa Kitazawa

This inventor holds 10 USPTO granted patents and 16 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Public University Corporation Nara Medical University, Sysmex Corporation. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takehisa Kitazawa. Retrieved from https://idiyas.com/inventor/takehisa-kitazawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 16)

% Patents Active = 70.0

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 154(Granted Patents)

Location History:

Gotenba, JP (2011)
Tokyo, JP (2019)
Shizuoka, JP (2015 - 2023)

Company Filing History:

10 out of 991

Chugai Seiyaku Kabushiki Kaisha

patents

2 out of 11

Public University Corporation Nara Medical University

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774327 - METHODS OF TREATMENT COMPRISING ADMINISTERING AN ANTIBODY THAT PROMOTES DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES (2026-10-27),

2. 11827699 - Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities (2023-11-28),

3. 11214623 - Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) (2022-01-04),

4. 11150254 - Method for measuring reactivity of FVIII (2021-10-19),

5. 11078518 - Method for evaluating blood coagulation reaction (2021-08-03),

6. 10450381 - Methods of treatment that include the administration of bispecific antibodies (2019-10-22),

7. 10302626 - Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein (2019-05-28),

8. 9334331 - Bispecific antibodies (2016-05-10),

9. 9175091 - Monoclonal antibody capable of binding to anexelekto, and use thereof (2015-11-03),

10. 8062638 - Prevention and treatment of diseases associated with blood coagulation (2011-11-22),

Title: Takehisa Kitazawa: Innovator in Antibody Production

Introduction

Takehisa Kitazawa is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of methods for producing antibodies. With a total of nine patents to his name, Kitazawa's work has the potential to impact medical treatments and diagnostics.

Latest Patents

Among his latest patents, Kitazawa has developed methods for producing antibodies that promote the disappearance of antigens with multiple biological activities. This innovative approach allows for the elimination of antigens from blood, thereby reducing physiological activities in vivo. Another notable patent involves the creation of antibodies capable of neutralizing substances that functionally substitute for coagulation factor VIII (FVIII). This advancement enables accurate evaluation of FVIII activity in hemophilia A patients, enhancing the effectiveness of diagnostic assays.

Career Highlights

Throughout his career, Takehisa Kitazawa has worked with esteemed organizations such as Chugai Seiyaku Kabushiki Kaisha and Nara Medical University. His experience in these institutions has allowed him to refine his research and contribute to significant advancements in antibody production.

Collaborations

Kitazawa has collaborated with notable colleagues, including Tetsuhiro Soeda and Tomoyuki Igawa. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Takehisa Kitazawa's contributions to the field of biotechnology through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in medical diagnostics and treatments.

Profile summary based on public USPTO records.